Vorapaxar in patients with coronary artery bypass grafting: Findings from the TRA 2°P-TIMI 50 trial
暂无分享,去创建一个
Marc P. Bonaca | E. Braunwald | D. Morrow | J. Morais | M. Tendera | B. Scirica | P. Théroux | M. Dellborg | Ethan C Kosova | T. Oude Ophuis | Ping He | P. Théroux
[1] Marc P. Bonaca,et al. Acute Limb Ischemia and Outcomes With Vorapaxar in Patients With Peripheral Artery Disease: Results From the Trial to Assess the Effects of Vorapaxar in Preventing Heart Attack and Stroke in Patients With Atherosclerosis–Thrombolysis in Myocardial Infarction 50 (TRA2°P-TIMI 50) , 2016, Circulation.
[2] V. Roger,et al. Secondary prevention after coronary artery bypass graft surgery: a scientific statement from the American Heart Association. , 2015, Circulation.
[3] Marc P. Bonaca,et al. Efficacy and Safety of Vorapaxar as Approved for Clinical Use in the United States , 2015, Journal of the American Heart Association.
[4] Marc P. Bonaca,et al. New ischemic stroke and outcomes with vorapaxar versus placebo: results from the TRA 2 °P-TIMI 50 trial. , 2014, Journal of the American College of Cardiology.
[5] C. Held,et al. Vorapaxar in acute coronary syndrome patients undergoing coronary artery bypass graft surgery: subgroup analysis from the TRACER trial (Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome). , 2014, Journal of the American College of Cardiology.
[6] Marc P. Bonaca,et al. Vorapaxar for secondary prevention of thrombotic events for patients with previous myocardial infarction: a prespecified subgroup analysis of the TRA 2°P-TIMI 50 trial , 2012, The Lancet.
[7] C. Vosa,et al. Aspirin plus clopidogrel for optimal platelet inhibition following off-pump coronary artery bypass surgery: results from the CRYSSA (prevention of Coronary arteRY bypaSS occlusion After off-pump procedures) randomised study , 2012, Heart.
[8] G. Weerakkody,et al. Mortality benefit with prasugrel in the TRITON-TIMI 38 coronary artery bypass grafting cohort: risk-adjusted retrospective data analysis. , 2012, Journal of the American College of Cardiology.
[9] Marc P. Bonaca,et al. Vorapaxar in the secondary prevention of atherothrombotic events. , 2012, The New England journal of medicine.
[10] Janet S. Wright,et al. 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Developed in collaboration with the American Association for Thoracic Surgery, Society of Cardiovascular Anesthesi , 2011, Journal of the American College of Cardiology.
[11] C. Held,et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery: results from the PLATO (Platelet Inhibition and Patient Outcomes) trial. , 2011, Journal of the American College of Cardiology.
[12] T. Schuster,et al. Enhanced Thrombin Generation After Cardiopulmonary Bypass Surgery , 2011, Anesthesia and analgesia.
[13] Shengshou Hu,et al. Aspirin plus clopidogrel therapy increases early venous graft patency after coronary artery bypass surgery a single-center, randomized, controlled trial. , 2010, Journal of the American College of Cardiology.
[14] Marc P. Bonaca,et al. Evaluation of a novel antiplatelet agent for secondary prevention in patients with a history of atherosclerotic disease: design and rationale for the Thrombin-Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2 degrees P)-TIMI 50 trial. , 2009, American heart journal.
[15] Marc P. Bonaca,et al. SCH 530348: a novel oral thrombin receptor antagonist. , 2009, Future cardiology.
[16] R. Colman,et al. Thrombin during cardiopulmonary bypass. , 2006, The Annals of thoracic surgery.
[17] A. Leger,et al. Protease-Activated Receptors in Cardiovascular Diseases , 2006, Circulation.
[18] S. Chackalamannil. Thrombin receptor (protease activated receptor-1) antagonists as potent antithrombotic agents with strong antiplatelet effects. , 2006, Journal of medicinal chemistry.
[19] S. Yusuf,et al. Benefits and Risks of the Combination of Clopidogrel and Aspirin in Patients Undergoing Surgical Revascularization for Non–ST-Elevation Acute Coronary Syndrome: The Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) Trial , 2004, Circulation.
[20] W. Karzai,et al. Aspirin and mortality from coronary bypass surgery. , 2003, The New England journal of medicine.
[21] D. Mangano. Aspirin and mortality from coronary bypass surgery. , 2002, The New England journal of medicine.
[22] J. Loscalzo. Vascular matrix and vein graft failure. Is the message in the medium? , 2000, Circulation.
[23] S. Yoshitake,et al. Antibody to thrombin receptor inhibits neointimal smooth muscle cell accumulation without causing inhibition of platelet aggregation or altering hemostatic parameters after angioplasty in rat. , 1998, Circulation research.
[24] E J Topol,et al. Aortocoronary saphenous vein graft disease: pathogenesis, predisposition, and prevention. , 1998, Circulation.
[25] W J Keon,et al. Coronary bypass graft fate and patient outcome: angiographic follow-up of 5,065 grafts related to survival and reoperation in 1,388 patients during 25 years. , 1996, Journal of the American College of Cardiology.
[26] B. Gersh. Aspirin Plus Clopidogrel Versus Aspirin Alone After Coronary Artery Bypass Grafting: The Clopidogrel After Surgery for Coronary Artery Disease (CASCADE) Trial , 2012 .
[27] R. Suri. Outcomes Following Pre-Operative Clopidogrel Administration in Patients With Acute Coronary Syndromes Undergoing Coronary Artery Bypass Surgery: The ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) Trial , 2010 .